

Data Sheet

WWW. UREIKO-CHEM. COM

Global Supplier of Chemical Probes, Inhibitors & Agonists

 Product Name
 :ND-011992

 Cat.No.
 :URK-V2515

 CAS No.
 :2446880-46-0

 $\begin{array}{ll} \mbox{Molecular Weight} & :381.35 \\ \mbox{Molecular Formula} & :C_{21}\mbox{H}_{14}\mbox{F}_3\mbox{N}_3\mbox{O} \\ \end{array}$

Target : Solubility :

HN

Biological Activity

ND-011992 is a novel potent and selective inhibitor of the Bruton's tyrosine kinase (BTK) with significant anti-tumor and anti-inflammatory effects.

BTK is a key signaling molecule involved in the maturation and activation of B cells, which plays a critical role in the pathogenesis of various diseases, including autoimmune disorders and cancers.

ND-011992 has potent anti-tumor activity against a wide range of cancer cell lines, including chronic lymphocytic leukemia, mantle cell lymphoma, and diffuse large B-cell lymphoma.

ND-011992 has shown to induce cell cycle arrest and apoptosis in cancer cells, while sparing normal cells, which highlights its potential as a safe and effective cancer therapy.

ND-011992 has shown to exhibit potent anti-inflammatory activity, which makes it a potential therapeutic option for autoimmune diseases such as rheumatoid arthritis and multiple sclerosis.

References

- 1. Sun et al. (2019). Discovery and preclinical characterization of ND-011992, a potent and selective BTK inhibitor for the treatment of B-cell malignancies. Cancer Res 79(14 Suppl): 4519-4519.
- 2. Pal Singh et al. (2021). ND-011992, a novel selective BTK inhibitor, improves clinical score and reduces cellular infiltration in experimental autoimmune encephalomyelitis (EAE) mouse model of multiple sclerosis (MS). FASEB J 35(S1): 1-1.

Note: All products of Ureiko are only used for scientific research or drug certificate declaration, we do not provide products and services for any personal use!